Thomas Cahill

CIK: 0001922939

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)2 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PRME

Prime Medicine, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

PRME
Prime Medicine, Inc.
Jun 5, 2026
Award(A)
Stock Option (right to buy)
Direct
75K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Disposition(D)
Stock Option (right to buy)
Direct
39.1K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Award(A)
Stock Option (right to buy)
Direct
39.1K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Disposition(D)
Stock Option (right to buy)
Direct
45K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Award(A)
Stock Option (right to buy)
Direct
45K shares-
PRME
Prime Medicine, Inc.
Jun 4, 2025
Award(A)
Stock Option (right to buy)
Direct
55K shares-

		Type	Shares	Price		Ownership
Jun 5, 2026	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	75,000	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Disposition(D) Stock Option (right to buy)	39,062	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	39,062	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Disposition(D) Stock Option (right to buy)	45,000	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	45,000	-	-	Direct
Jun 4, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	55,000	-	-	Direct

1-6 of 6 transactions

About Cahill Thomas

Cahill Thomas (SEC CIK 0001922939) files insider reports with the SEC as Director of Prime Medicine, Inc. (PRME).

Signal8 holds 3 ownership filings by Cahill Thomas, all Form 4s, filed between Jun 5, 2025 and Jun 8, 2026. Those filings report 6 transactions, from Jun 4, 2025 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cahill Thomas's filings is in CAMBRIDGE, MA.

Recent filings by Cahill Thomas

Jun 5, 2026: Grant or award of PRME derivative securities (Form 4, code A).
Aug 1, 2025: Disposition to issuer transaction of PRME derivative securities (Form 4, code D).
Aug 1, 2025: Grant or award of PRME derivative securities (Form 4, code A).
Aug 1, 2025: Disposition to issuer transaction of PRME derivative securities (Form 4, code D).
Aug 1, 2025: Grant or award of PRME derivative securities (Form 4, code A).

Other insiders filing for Prime Medicine, Inc. (PRME)

Schenkein David P, Director
Marrazzo Jeffrey D, Director
NELSEN ROBERT, Director
Kelly Michael Aaron, Director
Foster-Cheek Kaye I, Director
Chung Wendy, Director

How to read Form 4 transaction codes